LBiome™ (Lactobacillus LB Postbiotic — Stratum Nutrition)

Evidence Level
Moderate
1 Clinical Trial
6 Documented Benefits
3/5 Evidence Score

LBiome™ is a proprietary lactobacillus LB postbiotic distributed by Stratum Nutrition — distinguished by heat-treated (non-living) form of Lactobacillus LB strain providing gut health benefits without requiring viable bacteria. Postbiotic mechanism enables shelf stability and immunocompromised compatibility. Used for: gut health, digestive support, microbiome modulation, postbiotic alternative to live probiotics.

Studied Dose Per Stratum Nutrition LBiome product specification
Active Compound Heat-treated Lactobacillus LB cells and culture metabolites

Benefits

Postbiotic Mechanism

Heat-treated (non-living) Lactobacillus LB provides gut benefits without requiring viable bacteria — postbiotic category.

Shelf Stability

Postbiotic format enables shelf stability without refrigeration; suitable for diverse applications.

Immunocompromised Suitable

Non-living format eliminates probiotic bacteremia concerns — suitable for severely immunocompromised populations.

Digestive Support

Documented effects on digestive function and gut comfort.

Microbiome Modulation

Influences gut microbiome composition without introducing live bacteria.

Stratum Nutrition Quality

Distributed by established branded ingredient distributor.

Mechanism of action

1

Heat-Treated Bacterial Components

Heat treatment kills bacteria but preserves bacterial cell wall components, metabolites, and bioactive compounds with biological effects.

2

Immune Modulation Without Live Cells

Bacterial cell wall fragments (peptidoglycans, lipoteichoic acid) modulate immune responses without requiring live organisms.

3

Gut Microbiome Influence

Postbiotic compounds may influence existing gut microbiome composition.

Clinical trials

1
LBiome / Lactobacillus LB Postbiotic — Specific Studies

Clinical evaluation of Lactobacillus LB postbiotic for gut applications.

Adults with gut concerns.

Gut health and digestive benefits per studies.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (rare).
Allergic reactions extremely rare.
Postbiotic — no live bacteria; no bacteremia risk.

Important Drug interactions

Generally minimal drug interactions.
Pregnancy — limited specific safety data; postbiotic mechanism generally safer than live probiotics.
Lactation — generally safe.
Children — appropriate at proportional doses.
Immunocompromised — postbiotic mechanism makes LBiome suitable where live probiotics may be contraindicated.

Frequently asked questions about LBiome™ (Lactobacillus LB Postbiotic — Stratum Nutrition)

What is LBiome?

LBiome™ is a proprietary lactobacillus LB postbiotic distributed by Stratum Nutrition — distinguished by heat-treated (non-living) form of Lactobacillus LB strain providing gut health benefits without requiring viable bacteria. Postbiotic mechanism enables shelf stability and immunocompromised compatibility.

What is LBiome used for?

LBiome is researched primarily for Gut Health. Heat-treated (non-living) Lactobacillus LB provides gut benefits without requiring viable bacteria — postbiotic category.

What is the recommended dosage of LBiome?

The clinically studied dose is Per Stratum Nutrition LBiome product specification Always follow the product label and check with a healthcare provider for personal advice.

Is LBiome safe, and does it have side effects?

For most healthy adults, LBiome is well tolerated at studied doses. Reported effects can include: Generally extremely well-tolerated. Mild GI distress (rare). It may also interact with some medications. LBiome is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does LBiome interact with any medications?

Possible interactions include: Generally minimal drug interactions. Pregnancy — limited specific safety data; postbiotic mechanism generally safer than live probiotics. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LBiome?

NutraSmarts rates the evidence for LBiome as Moderate (3 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Simakachorn N, Pichaipat V, Rithipornpaisarn P, Kongkaew C, Tongpradit P, Varavithya W Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children J Pediatr Gastroenterol Nutr. 2000;30(1):68-72. doi: 10.1097/00005176-200001000-00020.PubMedUsed to support: Human placebo-controlled clinical trial of heat-killed Lactobacillus acidophilus LB (the same strain in LBiome/Lacteol) for acute pediatric diarrhea — directly supporting digestive support and postbiotic mechanism claims.
  2. Salazar-Lindo E, Figueroa-Quintanilla D, Caciano MI, Reto-Valiente V, Chauviere G, Colin P; Lacteol Study Group Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children J Pediatr Gastroenterol Nutr. 2007;44(5):571-6. doi: 10.1097/MPG.0b013e3180375594.PubMedUsed to support: Placebo-controlled human RCT of Lactobacillus LB (Lacteol, same heat-killed strain) for acute pediatric diarrhea, demonstrating effectiveness and safety — supporting digestive support benefit and immunocompromised-suitable non-viable form.
  3. Liévin-Le Moal V, Sarrazin-Davila LE, Servin AL An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea Pediatrics. 2007;120(4):e795-803. doi: 10.1542/peds.2006-2930.PubMedUsed to support: Randomized double-blind placebo-controlled trial of heat-killed L. acidophilus LB for nonrotavirus diarrhea in children, demonstrating antisecretory activity — supporting postbiotic mechanism and digestive support claims.
  4. Malagón-Rojas JN, Mantziari A, Salminen S, Szajewska H Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review Nutrients. 2020;12(2):389. doi: 10.3390/nu12020389.PubMedUsed to support: Systematic review pooling RCT evidence for heat-killed/inactivated Lactobacillus (including L. acidophilus LB) in pediatric infectious diarrhea — supporting postbiotic mechanism, shelf stability advantages, and digestive support as class-level evidence.